Skip to content
Finance Investment, Medical Health Aged Care

Medicinal cannabis company Little Green Pharma (ASX:LGP) records record quarterly revenue and cash receipts

Little Green Pharma 3 mins read

RECORD REVENUE AND CASH RECEIPTS FOR QUARTER AND FINANCIAL YEAR,

POSITIVE OPERATING CASHFLOW FOR FY24 OF $0.5 MILLION

 

Highlights 

  • Record quarterly cash receipts of $8.1 million, up over 50% on previous quarter and over 20% on previous corresponding period
  • Record quarterly revenue of $7.3 million (unaudited), up 34% on previous quarter and over36% on previous corresponding period
  • Record revenue of $25.6million (unaudited) for FY24, up nearly 30% on previous financial year resulting in positive operating cashflow of $0.5million for financial year
  • Cannabis legalised in Germany with its removal from the Narcotics List
  • Cash in bank of $5.0 million at 31 March 2024 up from $3.7 million at 31 December 2023

To view a copy of the company's Quarterly Activities Report lease click here

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

 


About us:

About Little Green Pharma Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution. The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains. Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets. The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems. For more information about Little Green Pharma go to: www.littlegreenpharma.comAbout Little Green PharmaLittle Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.For more information about Little Green Pharma go to: www.littlegreenpharma.comAbout Little Green PharmaLittle Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.For more information about Little Green Pharma go to: www.littlegreenpharma.com


Contact details:

David Tasker 

Chapter One Advisots

E: dtasker@chapteroneadvisors.com.au 

M: 0433 112 936

Media

More from this category

  • Medical Health Aged Care
  • 15/01/2025
  • 20:54
Glaxo SmithKline

Local scientific discovery Omjarra (momelotinib) TGA approved for Australians with rare bone marrow cancer

MELBOURNE PHOTO-FILMING OPPORTUNITY: THURSDAY 16TH JANUARY 2025 DATE: Thursday 16th January 2025 TIME: 10.30 – 11.30am LOCATION: 3 Torresdale Road, Toorak, Melbourne INTERVIEWEES: Prof…

  • Contains:
  • Business Company News, Finance Investment
  • 15/01/2025
  • 11:30
Wednesday 15 January 2025

IFM INVESTORS ANNOUNCES SIGNIFICANT GROWTH INVESTMENT IN SPLEND

IFM Investors is pleased to announce a significant investment in Splend Group Pty Ltd (Splend), an Australian-owned company that is a leading provider of subscription vehicles to rideshare drivers across Australia and the United Kingdom. IFM’s Growth Partners Fund 2 is investing in Splend alongside HESTA (through HESTA’s mandate with IFM) and other co-investors, to acquire a stake of 49% in the company. Founded in 2015, Splend has one of the largest electric vehicle fleets in Australia and is supporting rideshare drivers to adopt lower emission vehicles through its all-inclusive flexible finance and ownership offerings whilst improving their earnings capacity.…

  • Business Company News, Finance Investment
  • 15/01/2025
  • 10:35
ABX Group (ASX: ABX)

ABx Group’s subsidiary, ALCORE, enters into agreement with Rio Tinto Aluminium to establish continuous pilot plant near the Bell Bay aluminium smelter in northern Tasmania.

ABx Group Limited (ASX: ABX) ("ABx" or "the Company") and its 83%-owned subsidiary, ALCORE Limited ("ALCORE"), are pleased to announce that it has entered into a lease agreement with Rio Tinto Aluminium Limited for an industrial facility adjacent to its Bell Bay aluminium smelter in northern Tasmania. ALCORE will establish a pilot plant at the facility to demonstrate its world-first proprietary process to produce industrial chemicals, including hydrogen fluoride, from a waste product created during the aluminium smelting process. In the planned subsequent commercial plant, hydrogen fluoride will be converted to aluminium fluoride, an essential chemical for aluminium smelting that…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.